Williams & Connolly partner and Co-Chair of the firm’s Patent Litigation practice David Berl has been named among Bloomberg Law’s inaugural Unrivaled 2025 honorees.  According to the publication, these rankings “feature trial lawyers who lead the legal profession in high-stakes and impactful trials and settlements.”  Bloomberg spotlighted David’s success as lead counsel in a first-of-its-kind trial victory on behalf of Regeneron adverse to Mylan in its BPCIA (biosimilar) patent litigation concerning Regeneron’s market-leading and vision-saving biologic product, Eylea^®, a product with more than $6 billion in U.S. sales, as well as first-of-its-kind preliminary injunctions in BPCIA litigation regarding Eylea^® against three biosimilar manufacturers.  

In his interview with Bloomberg, David detailed his key to success in the trial: “plan[ning] for every contingency, advancing alternative arguments under Mylan’s interpretation of the claims that were both forceful and consistent with our primary arguments.  Our opponents had not done so.”  Additionally, “overcoming the adversity of a major, adverse pre-trial ruling enhanced the value of our ultimate trial victory.”

To read the full Bloomberg Law article, click here.